Company research / GTBP
GT Biopharma, Inc. (GTBP)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2020-12-31, GT Biopharma, Inc. reported revenue of $0.
Price chart
Annual financials
| Period ended | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | — | — |
| Operating Income | -$12.42M | — | — | -$14.36M | -$13.58M | -$21.26M | -$57.52M | -$6.76M | — | — |
| Net Income | -$28.35M | — | — | -$13.16M | -$7.60M | -$20.88M | -$58.01M | -$28.30M | — | — |
| EPS (Diluted) | $-6.68 | — | — | $-6.94 | $-5.64 | $-19.66 | — | — | — | — |
| Total Assets | $8.11M | $4.32M | $7.12M | $4.23M | $14.11M | $16.74M | $32.17M | $5.66M | — | — |
| Total Liabilities | — | $1.32M | $31.04M | — | $6.63M | $5.00M | $10.26M | — | — | — |
| Shareholders' Equity | $5.79M | $3.00M | -$25.88M | -$1.67M | $7.48M | $11.73M | $21.91M | -$29.43M | -$29.78M | -$27.50M |
| Cash & Equivalents | $6.81M | — | — | $3.95M | $1.08M | $5.67M | $8.97M | $5.30M | — | — |
| Operating Cash Flow | -$12.91M | — | — | -$12.90M | -$8.85M | -$15.22M | -$15.61M | -$7.26M | — | — |
| Shares Outstanding | 25.53M | — | — | 2.23M | 1.38M | 1.09M | 32.06M | 5.22M | — | — |
| Weighted Average Diluted Shares | 5.51M | — | — | 1.90M | 1.35M | 1.06M | — | 4.39M | — | — |
| EPS (Basic) | $-6.68 | — | — | $-6.94 | $-5.64 | $-19.66 | $-2.06 | — | — | — |